Skip to content
DataLookout
Menu

NCT03283878

Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial

StatusCompleted
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 58 versions: 34 with changes below, 16 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 17, 2026 Show 5 more changesShow less
    • Eligibility criteria expanded, about 17 words
    • Primary endpoint revised
    • Secondary endpoint revised
    • Study description revised
    • Site details revised at 2 of 14 sites
  2. Minor Trial status: Active, Not Recruiting to Completed
    • Study completion date changed from estimate of Dec 2025 to Aug 22, 2025
    v56
  3. Minor Study completion date: Aug 2025 to Dec 2025v54
  4. Minor Study title expanded, about 2 wordsv53
  5. Minor Primary completion date changed from estimate of Nov 2024 to Nov 20, 2024v49
Show 29 earlier versionsHide 29 earlier versions
  1. Minor Trial status: Recruiting to Active, Not Recruitingv46 Show 4 more changesShow less
    • Enrollment target: estimated 8000 to confirmed 1770
    • Study sites: 19 to 14
    • Primary completion date: Oct 2024 to Nov 2024
    • Study completion date: Oct 2024 to Aug 2025
  2. Minor Site contacts updated at 1 of 19 sitesv45
  3. Minor Site contacts updated at 1 of 19 sitesv44
  4. Minor Site details revised at 1 of 19 sitesv43
  5. Minor Site contacts updated at 1 of 19 sitesv42
  6. Minor Site details revised at 2 of 19 sitesv40
  7. Minor Site contacts updated at 1 of 19 sitesv38
  8. Notable Primary and study completion dates: Oct 2023 to Oct 2024
    • Site contacts updated at 1 of 19 sites
    v37
  9. Minor Site contacts updated at 1 of 19 sitesv36
  10. Minor Site contacts updated at 1 of 19 sitesv35
  11. Minor Site contacts updated at 1 of 19 sitesv34
  12. Minor Site details revised at 1 of 19 sitesv30
  13. Notable Primary and study completion dates: Oct 2022 to Oct 2023v29
  14. Minor Site contacts updated at 1 of 19 sitesv28
  15. Minor Site contacts updated at 2 of 19 sitesv27
  16. Minor Site details revised at 2 of 19 sitesv25
  17. Minor Site details revised at 1 of 19 sitesv23
  18. Minor Site details revised at 1 of 19 sitesv22
  19. Minor Site contacts updated at 1 of 19 sitesv20
  20. Minor Site details revised at 1 of 19 sitesv19
  21. Notable Primary and study completion dates: Oct 2021 to Oct 2022
    • Study sites: 18 to 19
    v18
  22. Minor Site contacts updated at 2 of 18 sitesv17
  23. Minor Study sites: 17 to 18v16
  24. Minor Site details revised at 5 of 17 sitesv15
  25. Notable Primary and study completion dates: Oct 2020 to Oct 2021
    • Study sites: 16 to 17
    v14
  26. Notable Eligibility criteria expanded, about 5 words
    • Study description revised
    • Site details revised at 6 of 16 sites
    • Collaborators: 1 to 2
    v13
  27. Minor Site details revised at 2 of 16 sitesv12
  28. Minor Study sites: 15 to 16v11
  29. Minor Study sites: 14 to 15v10
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants With Periprosthetic Infection (PJI) as Measured by Chart Review
Timeframe: up to 90 days post-operative

Secondary (1)

Costs of Antibiotic Treatment Per Participant

Arms and interventions

Study Group 1Experimental

Patients in Group #1 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. No further antibiotic administration will be given. \< 120 kg - patients will receive 2 grams of cefazolin ≥ 120 kg - patient will receive 3 grams of cefazolin Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. In addition, the use of clindamycin as an alternative is also permitted at a minimum recommended dose.

Study Group 2Experimental

Patients in Group #2 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. In addition, two weight-based doses of cefazolin will be administered within 24 hours postoperatively. \< 120 kg - patients will receive 2 grams of cefazolin ≥ 120 kg - patient will receive 3 grams of cefazolin Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. If allergic, patients will also receive two weight-based doses vancomycin postoperatively but not gentamicin postoperatively. In addition, the use of clindamycin as an alternative is also permitted. Vancomycin schedule: one dose preoperatively, one dose 8-12 h postoperatively, one dose 24 h postoperatively (opt.).

Drugs: Cefazolin

Sites

14 sites in 1 country